Yaoqiu Zhu 朱 耀球 Ph.D.
Previous appointment: Assistant Professor
Department of Chemistry and Biochemistry
Border Biomedical Research Center (NIH sponsored)
The University of Texas at El Paso


Web: http://www.thezhulab.org/

Email: zhuyq_pku@yahoo.com

Yaoqiu was born and grew up in Yiyang, Hunan, China.

He did undergradute research with Prof. Zhenfeng Xi and obtained B.S. of Chemistry in 2001 at Peking University. Under the supervision of Prof. Richard B. Silverman (inventor of Pfizer’s blockbuster drug Lyrica) at Northwestern University, he studied enzyme chemistry and got his Ph.D. in 2006.

With a strong interest in drug discovery, he then joined Abbott Laboratories/AbbVie as a senior research scientist. He conducted “structure and drug-like property relationship” studies for over 20 internal R&D projects and contributed to the discoveries of hepatitis C drug Viekira Pak and antileukemic drug Venclexta.

After worked at Abbott for over two years, he resigned and founded his own contract research company, MetabQuest. He built a medchem and organic synthesis lab in Beijing, China. He and his team have worked with pharmaceutical companies and research institutes on various medchem and preclinical projects. In addition, his lab has participated in several translational collaborations involving Harvard Medical School, University of Pittsburgh, Northwestern University, China Pharmaceutical University, Cambria Biosciences, etc.

To pursue his long-term goal of becoming a chemistry professor, since 2012, he has closed his company and devoted his lab to academic research, including investigation of the clinical drawbacks of clopidogrel (BMS and Sanofi's blockbuster drug Plavix) and discovery of novel cardiovascular medications. His independent resarch has yielded a series of publication as well as preclinical drug candidates. In the fall of 2015, he started a tenure-track assistant professor position at the University of Texas at El Paso.

On May 31, 2023, Yaoqiu departed El Paso, TX to join his family at the south bay coast in Los Angeles, CA. He continues his academic endeavor with extending to both NIH-funded collaborative studies and industry-sponsored pharmaceutical innovations.